BioSpace News Archive

Cordis has announced completion of patient enrollment in SUCCESS PTA, its large post-market study with the SELUTION SLR™ Drug-Eluting Balloon (DEB) for the treatment of patients with peripheral artery disease (PAD).

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.

Amgen announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts.

Masimo (NASDAQ: MASI) will release third quarter 2023 financial results for the period ended September 30, 2023, after the market closes on Tuesday, November 7, 2023.

IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.

Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Abivax SA today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs ").

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets.